San Diego, United States
Halozyme, Inc. is a groundbreaking biopharmaceutical company at the forefront of improving patient care through its cutting-edge technology, ENHANZE®. With a mission encapsulated in its slogan, "At Halozyme we continuously push the pace of innovation," the company is committed to transforming the treatment landscape by reducing hours-long patient therapies to mere minutes.
A key strength of Halozyme is its successful collaborative model with major pharmaceutical giants such as Roche, Pfizer, and Janssen. These partnerships leverage ENHANZE® technology to develop and commercialize new drug therapies, yielding revenue from achieved milestones and earned royalties. The company’s proprietary enzyme, rHuPH20, is central to these innovations, simplifying drug delivery and significantly enhancing the patient experience.
Halozyme’s proven track record, validated by impacting over 400,000 lives across 100 global markets, positions it as a compelling opportunity for investors seeking to back scalable, patient-centric healthcare solutions with substantial market potential and a strategic growth trajectory.
